Ruben A. Mesa, MD

Articles

Selection and Management of JAK Inhibitor Therapy in MF

June 9th 2022

Taking into account the three JAK inhibitors, ruxolitinib, fedratinib, and pacritinib, experts reflect on the appropriate use of each agent in myelofibrosis.

Dr. Mesa on the Future of JAK Inhibitor Therapy in Myelofibrosis

May 4th 2022

Ruben A. Mesa, MD, discusses the future of JAK inhibitor therapy in myelofibrosis.

A Brief Overview of Myeloproliferative Neoplasms

April 28th 2022

Expert Stephen Oh, MD, PhD, provides a broad overview of the myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis.

Dr. Mesa on the FDA Approval of Pacritinib in Intermediate- or High-Risk Myelofibrosis With Severe Thrombocytopenia

March 1st 2022

Ruben A. Mesa, MD, discusses the accelerated FDA approval of pacritinib (Vonjo) for the treatment of adult patients with intermediate or high-risk primary or secondary (post-polycythemia vera or post-essential thrombocythemia) myelofibrosis.

Dr. Mesa on Future Research Efforts With JAK Inhibitors in Myelofibrosis

January 21st 2022

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses future research efforts with JAK inhibitors in myelofibrosis.

Dr. Mesa on Navigating the Expanding Paradigm of JAK Inhibitors in MPNs

November 19th 2021

Ruben A. Mesa, MD, discusses strategies for navigating the expanding paradigm of JAK inhibitors in myeloproliferative neoplasms.

Dr. Mesa on the Impact of Molecular Biology on Therapeutic Development in Myelofibrosis

September 11th 2021

Ruben A. Mesa, MD, discusses the impact of molecular biology on therapeutic development in myelofibrosis.

Dr. Mesa on Achieving Transfusion Independence in Momelotinib-Treated Myelofibrosis

June 10th 2021

Ruben A. Mesa, MD, discusses the importance of achieving transfusion independence with momelotinib in myelofibrosis.

Dr. Mesa on the Potential Role of Momelotinib for Myelofibrosis-Associated Anemia

December 1st 2020

Ruben A. Mesa, MD, discusses the potential role of momelotinib in alleviating myelofibrosis-associated anemia.

Dr. Mesa on Management Strategies for MPNs

October 23rd 2020

Ruben A. Mesa, MD, discusses management strategies for patients with myeloproliferative neoplasms.

Dr. Mesa on Remaining Challenges Faced in MPN Treatment

October 15th 2020

Ruben A. Mesa, MD, discusses remaining challenges faced in the treatment of patients with myeloproliferative neoplasms.

Dr. Mesa on the Emergence of JAK Inhibitors in Myelofibrosis

September 11th 2020

Ruben A. Mesa, MD, discusses the emergence of JAK inhibitors in myelofibrosis.

Dr. Mesa on Current Data With Ruxolitinib and Fedratinib in Myelofibrosis

September 9th 2020

Ruben A. Mesa, MD, discusses current data with ruxolitinib and fedratinib in myelofibrosis.

Dr. Mesa on Accrual Considerations in MPN Clinical Trials

August 17th 2020

Ruben A. Mesa, MD, discusses accrual considerations in myeloproliferative neoplasms clinical trials.

Dr. Mesa on Developing Racially Inclusive Clinical Trials in MPNs

August 13th 2020

Ruben A. Mesa, MD, discusses the importance of developing racially inclusive clinical trials in myeloproliferative neoplasms.

Dr. Mesa on Racial Disparities in MPN, MDS, and AML Clinical Trials

August 10th 2020

Ruben A. Mesa, MD, discusses racial disparities in clinical trials for patients with myeloproliferative neoplasms, myelodysplastic syndrome, and acute myeloid leukemia.

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 3rd 2020

Ruben A. Mesa, MD, discusses the potential utility of CAR T-cell therapy in myeloproliferative neoplasms.

Dr. Mesa on Rechallenging With JAK Inhibitor Therapy in MPNs

July 23rd 2020

Ruben A. Mesa, MD, discusses the potential clinical benefit of rechallenging with JAK inhibitor therapy in patients with myeloproliferative neoplasms.

Dr. Mesa on Recent Data With Momelotinib in MPNs and Myelofibrosis

July 17th 2020

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses recent data with momelotinib in myelofibrosis.

Dr. Mesa on Treatment Advancements Made in MPNs

April 16th 2020

Ruben A. Mesa, MD, discusses advancements made in the treatment of patients with myeloproliferative neoplasms.